Comparative Pharmacology
Head-to-head clinical analysis: LAMIVUDINE STAVUDINE NEVIRAPINE versus LAMIVUDINE ZIDOVUDINE TABS 150MG 300MG CO PACKAGED WITH NEVIRAPINE TABS 200MG.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LAMIVUDINE STAVUDINE NEVIRAPINE versus LAMIVUDINE ZIDOVUDINE TABS 150MG 300MG CO PACKAGED WITH NEVIRAPINE TABS 200MG.
LAMIVUDINE; STAVUDINE; NEVIRAPINE vs LAMIVUDINE, ZIDOVUDINE TABS 150MG/300MG CO-PACKAGED WITH NEVIRAPINE TABS 200MG
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Lamivudine is a nucleoside reverse transcriptase inhibitor (NRTI) that inhibits HIV-1 reverse transcriptase by competing with natural substrate and causing chain termination. Stavudine is an NRTI that inhibits HIV-1 reverse transcriptase after intracellular phosphorylation to its active triphosphate form. Nevirapine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that binds directly to HIV-1 reverse transcriptase, causing allosteric inhibition.
Lamivudine is a nucleoside reverse transcriptase inhibitor (NRTI) that inhibits HIV reverse transcriptase via DNA chain termination after intracellular phosphorylation to lamivudine triphosphate. Zidovudine is also an NRTI that inhibits HIV reverse transcriptase after phosphorylation to zidovudine triphosphate. Nevirapine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that binds directly to reverse transcriptase, causing enzyme inhibition.
One tablet containing lamivudine 150 mg, stavudine 30 mg (or 40 mg if weight ≥60 kg), and nevirapine 200 mg orally twice daily.
One tablet of lamivudine/zidovudine (150 mg/300 mg) orally twice daily. One tablet of nevirapine (200 mg) orally once daily for 14 days, then one tablet twice daily thereafter.
None Documented
None Documented
Lamivudine: 5-7 h (prolonged in renal impairment); Stavudine: 1.6 h (prolonged in renal impairment, ~3.5-8 h in ESRD); Nevirapine: ~45 h (single dose), ~25-30 h (multiple doses due to autoinduction; prolonged in hepatic impairment).
Lamivudine: 5-7 hours (terminal half-life); prolonged to ~10-15 hours in advanced HIV infection; increased with renal impairment. Zidovudine: 0.5-3 hours (mean ~1 hour); prolonged to ~1.5-3 hours in renal impairment; intracellular active metabolite zidovudine-triphosphate has half-life ~3-7 hours. Nevirapine: ~25-30 hours (single dose), ~40-60 hours with multiple dosing (autoinduction reduces to ~20-30 hours after 2-4 weeks).
Lamivudine: ~70% renal (glomerular filtration and tubular secretion), ~30% unchanged; Stavudine: ~40% renal (tubular secretion), ~60% metabolized to inactive metabolites; Nevirapine: ~80% renal (metabolites, <5% unchanged), ~10% fecal.
Lamivudine: ~70% renal (glomerular filtration and active tubular secretion) as unchanged drug; ~30% metabolized to inactive metabolites (trans-sulfoxide) excreted renally. Zidovudine: ~75% renal (metabolite zidovudine-glucuronide) and ~20% unchanged; ~5% fecal. Nevirapine: ~80% renal (metabolites, mainly 2-hydroxy- and 3-hydroxy-nevirapine glucuronides), ~10% fecal, <5% unchanged.
Category A/B
Category A/B
NRTI
NRTI